Insulet (PODD) Q3 2026 earnings review
Insulet lifts its profit plan, but U.S. sales cool
Insulet, the maker of the Omnipod tubeless insulin pump, beat its profit and international sales targets while its core U.S. growth slowed further. Constant-currency sales rose 20% as a 33% international jump offset U.S. growth cooling to 15%. Chief executive Ashley McEvoy lifted the full-year margin expansion plan and announced a $1 billion buyback.
| Constant-currency revenue growth | +19.6% 17.5% - 19.5% plan (reported: $842M, +19.2%) |
|---|---|
| U.S. vs International Omnipod growth | +14.7% / +33.0% in constant currency |
| Operating margin, excluding one-offs | 22.0% +4.9 percentage points from a year ago |
| Full-year revenue and margin outlook | Raised revenue 21% - 22% (was 20% - 22%); margin +1.5 pts |
⚖️ Verdict: ⚪ Neutral
The story is unchanged because international strength and wider margins balanced out a weaker U.S. trajectory. Management finished its U.S. sales force expansion and tied sales pay to customer retention, but those steps started too late in the quarter to show up in revenue. One caution: keeping the full-year U.S. midpoint at 18% implies fourth-quarter U.S. growth slows to about 12% by our math.
The question now is whether lower retention among U.S. type 2 diabetes patients is a fixable onboarding issue or a permanent feature of that group. If the new sales incentives and support work, U.S. growth will rebound above the fourth-quarter floor; if they do not, the core business will settle into a low-teens pace. Fourth-quarter U.S. sales and the 2027 outlook on the next call will decide it.
🐂 Bull Case
Lower Production and Overhead Costs Lifted Margins
“Our team delivered a strong quarter, with revenue growth of nearly 20% and significant margin expansion,” chief executive Ashley McEvoy said. Insulet makes Omnipod, a wearable, tubeless insulin pump for people with diabetes. Even as U.S. sales slowed, the company turned a much larger share of revenue into profit and raised its full-year margin target.
- Operating margin excluding one-offs: 22.0%, up 4.9 percentage points from a year ago
- Cost of making the products: 24.9% of revenue, down 2.8 percentage points from a year ago by our math
- Selling and administrative overhead: 41.7% of revenue, down 3.0 percentage points from a year ago by our math
- Profit per share excluding one-offs: $1.99, up 59.9% from $1.24 a year ago
The margin jump matters because it shows the business can grow earnings fast even while spending on its U.S. sales force expansion. Reported gross margin also got a 0.9-point lift from a $7.2 million warranty credit on earlier product corrections, after $33.6 million of charges in the first half. Excluding that credit, gross margin still rose 2.0 percentage points to 74.2%.
What to watch: fourth-quarter operating margin excluding one-offs. By our math, the raised full-year outlook implies a 17.6% margin in the fourth quarter, and a reading above that would show whether third-quarter cost savings are permanent.
International Sales Drove the Revenue Raise
International markets now bring in nearly a third of Insulet's revenue and are carrying its top-line beats. Outside the U.S., sales of Omnipod grew 33.0% in constant currency (31.7% as reported) to $266.2 million, beating the company's 28% to 30% plan. During the quarter, the device maker connected Omnipod 5, its automated insulin pump, with Abbott's FreeStyle Libre 3 Plus blood-sugar sensor across ten international markets.
Because international demand stayed strong even against last year's 39.9% launch comparison, management raised its full-year international constant-currency growth outlook for a third time this year, to 32% to 33%. That 1.5-point increase at the middle of the range lifted the total company revenue outlook by half a point. By our math, the full-year plan implies about 22.7% international constant-currency growth in the fourth quarter.
What to watch: fourth-quarter international constant-currency growth against the 22.7% rate implied by the full-year outlook. Clearing that bar would show that newer sensor integrations are offsetting the lap of last year's country launches.
Omnipod Discover and Clinical Trials Advance
Insulet is using software and new clinical trials to keep patients on its pumps longer and expand into type 2 diabetes. It completed the full U.S. release of Omnipod Discover, a data platform that gives blood-sugar insights to patients and doctors. Global adoption reached more than 35,000 users and 5,000 healthcare professionals, up from 12,000 users and 1,600 clinicians last quarter.
The pump maker also rolled out its Omnipod 5 algorithm update to all U.S. retail pharmacies, noting real-world evidence of “better user outcomes with less effort”. In its pipeline, the company finished enrolling patients in STRIVE2, a trial for its next-generation Omnipod 6 pump, and EVOLVE, a pivotal study “supporting the development of fully closed-loop automated insulin delivery (AID) for adults with type 2 diabetes”.
What to watch: the regulatory filing date for the type 2 closed-loop system in 2027, and whether management shares retention numbers for Omnipod Discover users on the conference call.
🐻 Bear Case
U.S. Sales Slowed and Retention Remains Unquantified
U.S. Omnipod brings in 67.7% of total revenue, and last quarter Insulet cut its U.S. outlook because newer type 2 diabetes patients dropped off the pump faster than expected. This quarter, McEvoy said the team is “making continued progress on our type 2 action plan”. The company reported “completing U.S. sales force expansion and executing Type 2 action plan by improving onboarding and customer support, enhancing sampling, and aligning sales force compensation with new customer start and retention goals”.
Despite those steps, the U.S. numbers cooled further and the release gave no retention rate. U.S. Omnipod revenue grew 14.7% to $570.4 million, down from 20.1% in the second quarter and 28.3% in the first, landing below the 15.0% middle of the third-quarter plan. Management narrowed the full-year U.S. outlook to 17.5% to 18.5%, keeping the 18.0% midpoint unchanged.
Because the retention fixes only took effect in the third quarter on a 90-day patient onboarding cycle, this quarter's revenue could not test whether they worked. Worse, by our math, the unchanged full-year midpoint implies U.S. Omnipod growth slows to 11.9% in the fourth quarter, down from 28.0% a year ago.
What to watch: fourth-quarter U.S. Omnipod revenue growth against the 11.9% implied rate, alongside the 2027 U.S. outlook on the fourth-quarter call. A fourth-quarter print near 12% would show that type 2 patient drop-off is still dragging down the core business.
Factory Spending Cut Free Cash Flow by One-Third
While operating profit jumped, cash generation fell because Insulet is spending heavily on manufacturing capacity and working capital. Over the first nine months of 2026, free cash flow (operating cash flow minus capital spending) dropped 35.8% from a year ago to $211.7 million. By our math, third-quarter free cash flow was $66.3 million, down 33.8% from $100.1 million a year earlier.
Capital spending in the third quarter more than doubled from a year ago to $57.1 million (6.8% of revenue) by our math, as the company builds scale. Operating cash flow also slowed to $123.5 million in the quarter from $125.7 million a year ago because customer receivables and inventory grew faster than sales.
What to watch: full-year free cash flow in the fourth-quarter release. Management previously said full-year free cash flow would be down slightly from $377.7 million in 2025, which requires $166 million in the fourth quarter to reach flat.
Risks this quarter didn't answer
Four standing concerns from last quarter received no new numbers or updates in the third-quarter earnings release.
- Long-range growth target: management suspended its 20% multi-year growth plan last quarter, and the replacement is still scheduled for the fourth-quarter call.
- Tubeless pump competition and litigation: the release gave no update on the EOFlow trade-secret appeal or expected 2027 rival launches.
- Distributor concentration: three wholesalers made up 64% of revenue last quarter; the third-quarter breakdown awaits the 10-Q filing.
- U.S. pricing mix: whether pharmacy access rebates are weighing on revenue per customer was not addressed in the release.
👓 Other Themes
Insulet Launches a $1 Billion Buyback Plan
Insulet's board approved a $1 billion share repurchase programme, and management plans to spend about $400 million of it in the fourth quarter using existing cash. McEvoy said the buyback “demonstrates our confidence in the strength of the Omnipod platform and Insulet's long-term trajectory”. The company ended September with $584.4 million in cash and $962.1 million in total debt, after pausing buybacks in the second quarter.
💲 Other KPIs
Uncollected bills from customers rose 49.1% from a year ago and 17.0% from last quarter, more than double the 19.2% pace of revenue growth. Since the end of 2025, receivables have climbed by $172.1 million, holding back operating cash flow.
Stock on hand grew 23.7% from a year ago and 13.9% from the second quarter, up from $484.8 million in June. The $99.5 million build since December 2025 tied up cash as the company expanded international sensor compatibility and U.S. retail supply.
Diluted shares fell 1.7% from 70.7 million a year ago because of the $300 million share repurchase in the first quarter and last year's convertible debt redemption. Shares rose slightly from 69.4 million in the second quarter before the new fourth-quarter buyback begins.
🔮 Guidance
Raised. Insulet lifted the bottom of its full-year constant-currency revenue growth outlook by 1 percentage point, moving the middle of the range up 0.5 points to 21.5% (22% to 23% on a reported basis). By our math, that leaves about 15.9% constant-currency growth for the fourth quarter, down from 19.6% in the third quarter and 29.0% a year ago. Across four updates this year, the midpoint moved +1.0, -1.0, and +0.5 points.
Unchanged at the middle of the range. Management narrowed the U.S. growth band by half a point on each side, keeping the midpoint at 18.0% after cutting it by 3 points last quarter. By our math, the 18.0% midpoint implies U.S. Omnipod growth slows to 11.9% in the fourth quarter, compared with 14.7% in the third quarter and 28.0% in the fourth quarter of 2025.
Raised. The company lifted its international constant-currency growth plan by 1.5 percentage points at the middle of the range to 32.5% (35% to 36% on a reported basis, including a 3-point currency benefit). It is the third raise in three quarters: +2.0 points, +4.0 points, and +1.5 points. By our math, the outlook implies 22.7% constant-currency growth in the fourth quarter against a 41.7% year-ago comparison.
Unchanged at the middle of the range. The pump maker narrowed its total Omnipod constant-currency growth range while keeping the 22.0% midpoint steady (22.5% to 23.5% on a reported basis). After 25.1% constant-currency growth in the first nine months, the midpoint implies fourth-quarter Omnipod growth slows to about 15.1% by our math.
Unchanged. Management kept its forecast for non-insulin drug delivery revenue to fall about 40% for the year. Because revenue in the first nine months was $14.6 million (down 54.7%), hitting a 40% full-year decline on the $34.1 million 2025 base implies fourth-quarter revenue of about $5.9 million, up from $2.0 million a year ago by our math.
Raised. The outlook for full-year operating margin excluding one-offs moved up by 0.5 percentage points to about 1.5 percentage points of expansion over the 17.6% margin in 2025, pointing to 19.1% for 2026. After delivering 19.7% in the first nine months and 22.0% in the third quarter, the target implies a 17.6% margin in the fourth quarter by our math.
Unchanged. Management kept its floor of more than 30% growth in diluted profit per share excluding one-offs, over the $4.97 earned in 2025. Because the company already earned $5.06 per share in the first nine months (up 47.5% from $3.43 a year ago), it has already cleared the full-year 2025 total with one quarter left.
❓ Key Questions
What is the 90-day retention rate for type 2 patients?
Management said it aligned sales pay with customer retention and improved onboarding, but still has not published the type 2 retention rate or the gap versus type 1 users. Without that number, investors cannot tell if the U.S. slowdown is temporary or permanent.
Why does the U.S. outlook imply 12% Q4 growth?
By our math, keeping the full-year U.S. Omnipod growth midpoint at 18% leaves fourth-quarter growth at 11.9%, down from 14.7% in the third quarter. Did U.S. new customer starts slow down, or is management building extra caution into the fourth-quarter plan?
How much did Omnipod Discover lift patient retention?
Omnipod Discover grew from 12,000 users in the second quarter to more than 35,000 users after its full U.S. rollout. Management previously linked the platform to better retention, so quantifying the exact retention lift on this larger user base would test that claim.
Why did accounts receivable jump 49% from a year ago?
Accounts receivable reached $689.0 million, growing more than twice as fast as third-quarter revenue and weighing on operating cash flow. Is the increase driven by extended payment terms with its three main U.S. distributors or by faster international expansion?
What is the updated free cash flow and capex plan?
Capital spending more than doubled in the third quarter to $57.1 million by our math, and nine-month free cash flow is down 35.8% to $211.7 million. With $400 million of buybacks planned for the fourth quarter, what is the full-year cash flow target?